Santen Pharmaceutical Co., Ltd.
Notice Regarding Filing for Commencement of Bankruptcy Proceedings by Our Consolidated Subsidiary
A consolidated subsidiary, Chongqing Santen Kerui Pharmaceutical Co., Ltd., has filed a petition for commencement of bankruptcy proceedings with the local court. Total liabilities amount to 143 million CNY (approximately 3.3 billion yen). As the Company and its subsidiaries have fully provided allowance for doubtful accounts for the related debts, the impact on the Company's consolidated results is expected to be minor. Bankruptcy proceedings are expected to proceed with asset disposals and distributions to creditors.
Key Figures
- Total liabilities: 143 million CNY (approx. 3.3 billion yen)
- Loans receivable from the Company: 20 hundred million yen
- Equity valuation: 0 yen
AI要約
Overview of the News
A consolidated subsidiary of Santen Pharmaceutical Co., Ltd., Chongqing Santen Kerui Pharmaceutical Co., Ltd., resolved to file a petition for commencement of bankruptcy proceedings on local time October 16, 2026. The decision follows changes in the business environment due to regulatory reforms in the Chinese market. Although liquidation was resolved in October 2024, prospects for asset sales and full repayment of liabilities did not materialize, leading to the filing for bankruptcy proceedings.
Expected Impact and Response
The Company holds loans receivable from the subsidiary, but these have been fully provided for as allowance for doubtful accounts; therefore, the impact on the Company's consolidated results for fiscal year 2026 is expected to be minor. Once bankruptcy proceedings advance and the court issues a bankruptcy declaration, assets are expected to be disposed of and distributions made to creditors. The equity valuation of Chongqing Kerui Pharmaceutical has been recorded as 0 yen, and the effect on related parties is limited.
Santen Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
